Unilife Enters Definitive Global Strategic Agreement With AbbVie
On January 15, 2015, Unilife Corporation (Unilife) entered into a definitive global strategic agreement with AbbVie Inc. (AbbVie) for the customization and supply of its injectable drug delivery systems for use with AbbVie’s drug portfolio. Unilife has been selected by AbbVie as a preferred partner for the customization and supply of innovative, differentiated drug delivery systems. AbbVie will pay $5 million for the exclusive right to form and enter into a mutually agreeable development and supply agreement with Unilife to include exclusive access to the Unifill FinesseTM prefilled syringe and the LISATM reusable auto-injector for target therapies within AbbVie’s drug portfolio for the treatment of auto-immune diseases, as well as associated exclusivity fees. The target therapies and conditions for which these systems will be used are confidential under the terms of the agreement.
About the Unifill FinesseTM
The Unifill Finesse is a product configuration from Unilife’s proprietary platform of ready-to-fill (prefilled) syringes with integrated, automatic needle retraction. Designed for integration with standard filling and packaging lines, it utilizes a standard plunger and plunger rod.
About the LISATM Reusable Auto-Injector
The LISA reusable auto-injector is an automated and highly customizable product that can be used by a patient to perform hundreds of injections. Patients can control the speed of dose delivery to help minimize pain or discomfort during an injection. It allows for the removal of a used Unifill syringe with a retracted needle for safe, compact, and convenient disposal. Other features include a single activation button, LED indicators and a push-on skin sensor to minimize potential drug wastage. Customization options include Bluetooth, Wi-Fi, or 3G connectivity.
About Unilife Corporation
Unilife Corporation (NASDAQ:UNIS/ASX: UNS) is a US-based developer and commercial supplier of injectable drug delivery systems. Unilife’s portfolio of innovative, differentiated products includes prefilled syringes with automatic needle retraction, drug reconstitution delivery systems, auto-injectors, wearable injectors, ocular delivery systems and novel systems. Products within each platform are customizable to address specific customer, drug, and patient requirements. Unilife’s global headquarters and manufacturing facilities are located in York, PA. For more information, download the Unilife IRapp on your iPhone, iPad. or Android device, or to find out more about Unilife’s range of products and services, please contact a member of our commercial development team via www.unilife.com or +1 717 384 3400.
Total Page Views: 1704
